Fundraising FoxXyloCor Therapeutics
Malvern, US · Delaware corporation · 5 known investors
Find your way into XyloCor Therapeutics
Sign up to see every warm intro you have to XyloCor Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the XyloCor Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Founders & leadership
RC
Ronald CrystalFounder and Advisor (Board Observer)
TR
Todd RosengartFounder; Board Observer
JT
John TuckerPresident and CEO
AG
Albert GianchettiExecutive
Board
GB
JC
James CohenBoard director
Investors · 5
Lumira Ventures✓ confirmed by XyloCor TherapeuticsToronto · $1M – $10M
How we know: Lumira Ventures's portfolio page · the company's own site · Not right? Tell us
Fountain Healthcare Partners✓ confirmed by XyloCor TherapeuticsDublin · $10.8M – $16.2M
How we know: the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us
Jeito Capitallisted by Jeito CapitalParis
How we know: Jeito Capital's portfolio page · Not right? Tell us
Longwood Fundlisted by Longwood FundBoston
How we know: Longwood Fund's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$21.4M disclosed across 6 of 7 rounds · 2016–2025
▶$4MraisedJan 2021 · 5 investors · BiotechnologyRule 506(b)
▶$4MraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fouad Azzam, Ph.D.Director
- Aidan KingDirector
- Michael F. Powell, Ph.D.Director
- Todd K. Rosengart, M.D.Director
- Glenn BatchelderDirector
- Albert GianchettiExecutive Officer, Director
- Amount sold
- $4M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MraisedOct 2018 · 7 investors · BiotechnologyRule 506(b)
▶$16.8MraisedOct 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd RosengartDirector
- Glenn BatchelderDirector
- Albert GianchettiExecutive Officer, Director
- James CohenDirector
- Offering amount
- $16.8M
- Amount sold
- $16.8M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedJul 2018 · 1 investors · BiotechnologyRule 506(b)
▶$200KraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Glenn BatchelderDirector
- James CohenDirector
- Todd RosengartDirector
- Albert GianchettiExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $200K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$60KraisedMar 2018 · 4 investors · BiotechnologyRule 506(b)
▶$60KraisedMar 2018 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James CohenDirector
- Glenn BatchelderDirector
- Albert GianchettiExecutive Officer, Director
- Todd RosengartDirector
- Offering amount
- $150K
- Amount sold
- $60K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$100KraisedDec 2017 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedDec 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd RosengartDirector
- Glenn BatchelderDirector
- James CohenDirector
- Albert GianchettiExecutive Officer, Director
- Offering amount
- $100K
- Amount sold
- $100K
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$250KraisedNov 2016 · 1 investors · BiotechnologyRule 506(b)
▶$250KraisedNov 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Glenn BatchelderDirector
- James CohenDirector
- Albert GianchettiExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Capricor TherapeuticsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
CeleCor TherapeuticsCelecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.
ArecorAreCor develops proprietary pharmaceutical products for diabetes, obesity, and cardiometabolic diseases using its Arestat technology platform. The company targets areas of high unmet patient need in high-value therapeutic markets.
DalCor www.dalcorpharma.comDalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
AliveCorAliveCor develops digital health solutions focused on cardiovascular care, serving employers and healthcare payers seeking enterprise heart health platforms.
Companies working in the same space as XyloCor Therapeutics.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does XyloCor Therapeutics do?
- XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
- Who founded XyloCor Therapeutics?
- XyloCor Therapeutics was founded by Ronald Crystal, Todd Rosengart.
- Who are XyloCor Therapeutics's investors?
- XyloCor Therapeutics's investors include Lumira Ventures, Fountain Healthcare Partners, Jeito Capital, Longwood Fund, Sofinnova Ventures.
- How much funding has XyloCor Therapeutics raised?
- XyloCor Therapeutics has disclosed $21.4M raised across 6 of its 7 known rounds.
- Where is XyloCor Therapeutics headquartered?
- XyloCor Therapeutics is headquartered in Malvern, US.